An implantable collamer lens ® (ICL) V4c model (STAAR Surgical, Monrovia, CA, USA) was placed in the eye of a 31-year-old male patient with high myopia followed by the development of malignant glaucoma. After failing medical treatment for 5 days, a noncomplicated pars plana vitrectomy and anterior hyaloidectomy succeeded in breaking the aqueous misdirection. Sixteen months later, intraoperative miotics were purposefully withheld from the ICL surgery in the fellow eye and malignant glaucoma did not develop. Even though the patient's visual acuity postoperatively was 20/20, OU, a single small atrophic iris patch in the affected eye resulted in slightly more halos and glare in mesopic conditions as compared to the fellow eye. Earlier surgical intervention may have prevented iris ischemia and iridocorneal touch with its subsequent iris atrophy and resulted in an even more favorable visual outcome. Withholding intraoperative miotics during ICL surgery appeared to be beneficial in this case.
Introduction
M alignant glaucoma is a rare complication that has been reported in four cases following implantable collamer lens ® (ICL) (STAAR Surgical, Monrovia, CA, USA) implantation. [1] [2] [3] Even though the exact physiopathology of malignant glaucoma is not clear, anterior rotation of the ciliary body followed by the accumulation of aqueous within the posterior segment is the most acceptable theory proposed by Shaffer. [4] To better understand the mechanism and the most appropriate treatment for malignant glaucoma post-ICL surgery, we discuss this complication in a patient with bilateral ICL implantation.
To the best of our knowledge, this is the first reported case of malignant glaucoma following implantation of ICL with a good overall visual outcome enough for the patient to carry on with ICL surgery in the fellow eye.
Case Report
A 31-year-old male patient with bilateral high myopia presented for refractive surgery. His best-corrected visual acuity was 20/20 in both eyes (OD: −11.00, OS: −12.50 + 0.50 × 95). Both eyes were to receive an ICL. Left eye was to be operated on first.
A single peripheral Nd: YAG laser iridotomy was performed at 12 o'clock, 2 months preoperatively in both eyes.
On the day of surgery, a full preoperative pupillary dilation was achieved using tropicamide drops. Under general anesthesia, an ICL V4c model (−13.00 D, VICMO 12.6 mm) was inserted in the anterior chamber (AC) through a 3.0-mm corneal incision at 3 o'clock. After repositioning This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
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The postoperative period was uncomplicated, with an uncorrected visual acuity of 20/20.
Discussion
To our knowledge, this is the first reported case of a unilateral malignant glaucoma following bilateral ICL implantation. A thorough literature review revealed four cases of malignant glaucoma post-ICL surgery [ Table 1 ]. [1] [2] [3] 5] None of these cases had a favorable overall visual outcome to undergo ICL implantation in the fellow eye.
Three theories might explain the occurrence of aqueous misdirection: ciliary body irritation and inflammation leading to anterior rotation of the ciliary process, [5] laser iridotomy, [6] or the use of miotics. [7] Fourman proposed that miotic therapy was the inducing factor of malignant glaucoma postlaser iridotomy since all the reported cases of aqueous misdirection postiridotomy received pilocarpine and it would be impossible to implicate the performance of a laser iridotomy as the primary cause. [8] The surgical technique in all four reported cases of aqueous misdirection post-ICL implantation included intraoperative Miochol. In our case, the preoperative AC depth was similar in both eyes, laser iridotomy was performed preoperatively bilaterally, the ICL implants were inserted by the same experienced surgeon (J.K.) using the same technique, and both implants had similar dimensions. The only difference between both surgeries was the intraoperative use of Miochol in the affected eye, which, according to the aforementioned literature, could have contributed to the aqueous misdirection.
As such, withholding miotic agents from routine ICL surgery, especially when the surgeon is comfortable with the ICL placement behind the iris, could help prevent malignant glaucoma. Should the use of miotics be necessary, we recommend that they be used judiciously.
Medical management (mydriatic drops, antiglaucoma drugs, and mannitol) is the first line of treatment in malignant glaucoma. However, it has a low success rate of <50%. [9] If medical treatment is unsuccessful in phakic patients, pars plana vitrectomy (PPV) with hyaloidotomy is the treatment of choice with a high success rate. [9] In cases of malignant glaucoma, especially in ICL surgery patients, a timely resolution of the aqueous block is necessary to ensure a desirable overall postsurgical outcome. As such, establishing an early and correct diagnosis is crucial, having a preoperative the ICL behind the iris, the viscoelastic was removed using irrigation. Miochol ® -E (acetylcholine chloride intraocular solution) was injected in the AC at the end of the procedure, and all wounds were irrigated with balanced salt solution.
On the 1 st postoperative day, the patient presented with eye pain and blurry vision; anterior displacement of lens-iris diaphragm was noted on slit-lamp examination with an AC depth approximating 1 corneal thickness centrally. Furthermore, a closed angle was noted on gonioscopy in addition to a high intraocular pressure (IOP). The iridotomy was patent and there were no signs of pupillary block. Ultrasound B ruled out suprachoroidal hemorrhage and vaulting of the ICL was excluded by an anterior-segment optical coherence tomography. Hence, the diagnosis of malignant glaucoma was made.
M e d i c a l t r e a t m e n t ( c o m b i n a t i o n o f t o p i c a l
brimonidine/timolol, bimatoprost, brinzolamide, and atropine, in addition to oral acetazolamide) failed over the following 5 days to normalize the pressure and reform the AC. Subsequently, a noncomplicated posterior pole 20-gauge vitrectomy with disruption of the anterior hyaloid face was performed, leading to resolution of the aqueous misdirection and normalization of IOP. The patient achieved 20/20 uncorrected visual acuity with excellent placement of his ICL. However, a relatively small single area of iris atrophy secondary to iridocorneal touch along with a slightly dilated pupil developed [ Figure 1 ], causing mild halos and glare under mesopic conditions. Sixteen months later, an ICL V4c model (−12.00 D, VICMO 12.6 mm) was implanted in the right eye. The same operative technique was used except for purposefully withholding the intraoperative Miochol ® -E. patent iridotomy is helpful, and shortening the course of medical treatment in favor for an early PPV and hyaloidotomy is recommended.
Even though our patient's uncorrected visual acuity postoperatively was 20/20, OU, a single small atrophic iris patch in the affected eye resulted in slightly more halos and glare under mesopic conditions as compared with the fellow eye. Earlier surgical intervention may have prevented iridocorneal touch and ischemia and resulted in an even more favorable visual outcome.
Having an eye with malignant glaucoma increases the risk of its occurrence in the fellow eye. [10] It is possible that in this case, withholding intraoperative miotics helped prevent aqueous misdirection in the fellow eye.
Conclusion
We recommend withholding miotic agents from routine ICL surgery, especially when the fellow eye has malignant glaucoma. Early vitrectomy in cases of malignant glaucoma post-ICL implantation may result in a more favorable overall visual outcome.
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